VYXEOS®

Drug Information Related Patent

Hold Company

Jazz Pharmaceuticals

Learn More

Dosage and Administration

POWDER;INTRAVENOUS

Specification

100MG;44MG

Indication

VYXEOS® is indicated for the treatment of newly diagnosed treatment-related acute myeloid leukemia (tAML) or AML with AML-MRC in adults and children aged 1 year and older.

Use

Instructions for Use

API

CYTARABINE
DAUNORUBICIN

API Structure

We Supply

CYTARABINE

Note:

In-house Standard
Facility GMP

DAUNORUBICIN

Note:

USP
Facility GMP
Product GMP
China DMF

null

Note:

null

Drug Patent

Patent No	Expiration Date
10028912	2032/10/15
10166184	2032/10/15
10835492	2032/10/15
7850990	2027/1/23
8022279	2027/9/14
8092828	2029/4/1
8431806	2025/4/22
8518437	2026/6/7
9271931	2027/1/23

API Patent

Patent No	Expiration Date
7850990	2027/1/23
8022279	2027/9/14
8092828	2029/4/1
8431806	2025/4/22
9271931	2027/1/23

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION